...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Anacetrapib Officially Bites the Dust

This is not too much of a surprise, based upon the data revealed at ESC 2017 in August. However, it's official. Another nail in the coffin for CETP inhibitors. Long live apabetalone!

"Positive PhIII can’t salvage Merck’s anacetrapib, now relegated to the scrap heap" by John Carroll, Endpoint News

Share
New Message
Please login to post a reply